Curanex Pharmaceuticals Inc. (CURX) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Curanex Pharmaceuticals Inc. is a developmental-stage biotechnology company focused on discovering and commercializing botanical drugs for inflammatory diseases. The Company completed its Initial Public Offering (IPO) in August 2025 and trades on the Nasdaq Capital Market. Its lead candidate, Phyto-N, is in preclinical development for ulcerative colitis, with recent expansion into cancer cachexia.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,150,228) | $(137,583) |
| Operating Expenses | $3,183,359 | $137,452 |
| Cash and Cash Equivalents (End of Period) | $4,018,574 | $198,943 |
| Total Assets | $8,411,292 | $11,580,124 |
| Total Liabilities | $332,644 | $361,040 |
| Net Cash Used in Operating Activities | $(954,560) | $(149,948) |
Note: The Company has no debt obligations as of March 31, 2026. Related party loans were fully repaid in September 2025.
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased by approximately $3.04 million compared to Q1 2025. This was driven by a $2.26 million increase in Research & Development (R&D) expenses and a $0.79 million increase in General & Administrative (G&A) expenses.
- R&D Activity: R&D expenses were $0 in Q1 2025 but rose to $2.26 million in Q1 2026, reflecting significant investment in IND-enabling studies (toxicology, pharmacokinetics) and CRO/CDMO fees following the IPO.
- G&A Increase: G&A expenses rose primarily due to the commencement of cash compensation for the founder and senior management post-IPO, alongside increased professional fees for public company compliance.
- Liquidity Position: Cash balances increased significantly from $198,943 in Q1 2025 to $4.02 million in Q1 2026, attributable to net proceeds of approximately $15.3 million from the IPO and over-allotment exercise in late 2025.
Outlook, Risks, and Management Commentary
- Development Milestones: The Company completed a GMP pilot-scale batch of Phyto-N in February 2026 and a dose-range finding toxicology study in March 2026. Management targets an Investigational New Drug (IND) submission for ulcerative colitis in the fourth quarter of 2026.
- Pipeline Expansion: In April 2026, the Company added cancer cachexia as a new core indication to its pipeline.
- Nasdaq Compliance Risk: The Company received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. It has been granted a second 180-day compliance period ending November 2, 2026. Management may implement a reverse stock split to regain compliance.
- Going Concern: Management has alleviated substantial doubt regarding the Company's ability to continue as a going concern, citing strong cash reserves from the IPO sufficient to fund operations for at least the next 12 months.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026.
Investor Verification Checklist
- Nasdaq Listing Status: Verify the Company's progress in meeting the $1.00 minimum bid price requirement by the November 2, 2026 deadline to avoid delisting.
- Cash Burn Rate: Monitor the rate of cash consumption against the $4.0 million balance to ensure sufficiency for the targeted Q4 2026 IND submission.
- Internal Controls: Review future filings for remediation plans regarding the ineffective disclosure controls and procedures.
- R&D Progress: Confirm the successful initiation of GLP toxicology studies and the timeline for the IND submission.
- Stock Issuances: Note the issuance of 24,000 shares to the Chief Scientific Officer in March 2026 as compensation, subject to a 12-month trading lock-up.